
SAGE Earnings
SAGE Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of SAGE Therapeutics Inc(SAGE) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of SAGE Therapeutics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-07-30 | - | -0.96 | - | - | 16.73M | 31.66M | +89.23 | -0.23 | -0.23 |
FY2025Q1 | 2025-04-29 | After Hours | -0.99 | -1.01 | -2.02 | 14.01M | 14.06M | +0.40 | -4.08 | -5.66 |
FY2024Q4 | 2025-02-11 | After Hours | -1.45 | -1.56 | -7.59 | 14.37M | 12.82M | -10.81 | -0.42 | -2.09 |
FY2024Q3 | 2024-10-29 | After Hours | -1.52 | -1.53 | -0.66 | 10.85M | 11.87M | +9.37 | -24.06 | -29.95 |
FY2024Q2 | 2024-07-31 | - | -1.68 | -1.70 | -1.19 | 8.87M | 8.65M | -2.40 | +1.39 | -21.02 |
FY2024Q1 | 2024-04-25 | - | -1.63 | -1.80 | -10.43 | 5.19M | 7.90M | +52.34 | -3.00 | -5.14 |
FY2023Q4 | 2024-02-14 | - | -1.18 | -0.55 | +53.39 | 60.98M | 77.97M | +27.87 | +11.86 | -3.56 |
FY2023Q3 | 2023-11-07 | - | -2.64 | -2.81 | -6.44 | 3.17M | 2.72M | -14.42 | -4.75 | -16.01 |
FY2023Q2 | 2023-08-07 | - | -2.53 | -2.68 | -5.93 | 2.91M | 2.47M | -15.10 | -53.60 | -39.70 |
- | 2023-05-02 | - | -2.50 | -2.46 | +1.60 | - | - | - | -6.35 | +5.82 |
SAGE Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, SAGE Therapeutics Inc reported performance for FY2025Q2, announced on 2025-07-30. The company achieved an EPS of , compared to analyst estimates of -0.96 by % . Revenue for the quarter reached 31.66M compared to expectations of 16.73M by 89.23% .
The stock price reacted with a -0.23% one-day change and a -0.23% five-day change following the earnings release. These movements reflect market reaction in SAGE Therapeutics Inc growth trajectory and strategic initiatives.
SAGE Earnings Forecast
Looking ahead, SAGE Therapeutics Inc(SAGE) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 24.63M and an EPS of -0.87.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 18.84%, while EPS estimates have been Revise Downward by -0.14%. For the upcoming Q3 2025, revenue estimates have been adjusted Revise Downward by -3.34% . These revisions correlate with a 31.32% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in SAGE Therapeutics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between SAGE's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward

+18.84%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-0.14%
In Past 3 Month
Revenue Estimates for Q3 2025
Revise Downward

-3.34%
In Past 3 Month
Stock Price
Go Up

+31.32%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:90.71M
--
EPS Estimate-Annual FY 2025:-3.61
—
Stock Price8.68
SAGE Revenue and EPS Performance: A Historical Perspective
SAGE Therapeutics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-07-30,):
EPS: (Actual) vs.-0.96 (Estimate) (%)
Revenue: 31.66M (Actual) vs. 16.73M (Estimate) (89.23%)
Price Reaction: -0.23%(1-Day), -0.23%(5-Day)
FY2025Q1 (2025-04-29,After Hours):
EPS: -1.01 (Actual) vs.-0.99 (Estimate) (-2.02%)
Revenue: 14.06M (Actual) vs. 14.01M (Estimate) (0.40%)
Price Reaction: -4.08%(1-Day), -5.66%(5-Day)
FY2024Q4 (2025-02-11,After Hours):
EPS: -1.56 (Actual) vs.-1.45 (Estimate) (-7.59%)
Revenue: 12.82M (Actual) vs. 14.37M (Estimate) (-10.81%)
Price Reaction: -0.42%(1-Day), -2.09%(5-Day)
Earnings Reaction
The chart below shows how SAGE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SAGE sees a +18.31% change in stock price 10 days leading up to the earnings, and a -6.95% change 10 days following the report. On the earnings day itself, the stock moves by -5.85%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed % on the day following the earnings release and then changed by 0% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
SAGE Therapeutics Inc (SAGE) Q1 2025 Earnings Call Summary
Neutral
2025-04-29
The earnings call presents mixed signals. Financial performance shows improvement in net loss and revenue growth, but a significant cut in R&D expenses could hinder future product development. The Q&A section reveals optimism about ZURZUVAE's growth, yet management's avoidance of specific metrics raises concerns. The ongoing shareholder return plan lacks clarity, and the market strategy hinges on sustained demand. Without a market cap, the stock's reaction is uncertain, leading to a neutral prediction.
SAGE Therapeutics Inc (SAGE) Q1 2025 Earnings Call Summary
Positive
2025-04-29
The earnings call presents a positive outlook with strong financial performance, including a 21% increase in collaboration revenue and a significant reduction in net loss. The company has a solid cash runway and expects XERZUVEY to be cash flow positive by 2026. Despite some uncertainties in the R&D pipeline, the sales force expansion and high awareness among physicians are promising. The Q&A section revealed strong demand and revenue growth, reinforcing the positive sentiment. However, the lack of specific guidance metrics is a minor concern. Overall, the positive factors outweigh the negatives.
Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Summary
Neutral
2024-10-30
The earnings call presents mixed signals. Strong revenue growth (49% QoQ) and decreasing operating expenses are positive, but financial losses and pipeline setbacks, including termination of key collaborations, raise concerns. Management's avoidance of guidance and lack of shareholder return plan further tempers enthusiasm. Overall, the sentiment is neutral due to balanced positives and negatives.
Sage Therapeutics, Inc., (SAGE) Q2 2024 Earnings Call Summary
Positive
2024-08-01
The earnings call summary indicates a positive outlook with strong initial revenue from ZURZUVAE, decreased operating expenses, and solid financial health. The Q&A section supports this with indications of strong demand, successful payer engagement, and strategic expansion plans. Despite a net loss, the company is positioned for growth with optimistic guidance and strategic initiatives. The market strategy and shareholder return plan are well-received, leading to an overall positive sentiment for the stock price over the next two weeks.
People Also Watch

TKNO
Alpha Teknova Inc
4.880
USD
+2.09%

BAND
Bandwidth Inc
14.440
USD
+4.87%

ZVRA
Zevra Therapeutics Inc
9.430
USD
-19.81%

TRC
Tejon Ranch Co
17.470
USD
-0.80%

MERC
Mercer International Inc
3.050
USD
+5.90%

BIOX
Bioceres Crop Solutions Corp
3.120
USD
-1.89%

VBNK
Versabank
10.650
USD
+2.60%

VALU
Value Line Inc
38.960
USD
+0.57%

NRIM
Northrim BanCorp Inc
87.750
USD
+0.69%

CLDT
Chatham Lodging Trust
7.270
USD
+2.11%
FAQ

What were the key highlights of SAGE’s latest earnings report for FY2025Q2?
SAGE reported its FY2025Q2 earnings on 2025-07-30, showcasing a revenue of 31.66M against an estimate of 16.73M, resulting in a 89.23% surprise. The EPS was 0, surpassing the expected -0.96 by 0% . The stock experienced a -0.23% price change on the earnings day and a -0.23% change over the next five days, reflecting market reactions to the results.

How did SAGE’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for SAGE for 2025/Q3?

How does SAGE’s stock price correlate with earnings forecast revisions?

What should investors expect from SAGE’s next earnings report?
